1. a confirmed diagnosis of covid 19, rsv infection, or influenza ≤120 days before study intervention administration. 2. history of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 3. immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 4. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. 5. allergy to egg proteins (egg or egg products) or chicken proteins. 6. any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 7. receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study. 8. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study. 9. receipt of any rsv vaccine at any time prior to enrollment, or planned receipt throughout the study. 10. receipt of any influenza vaccine ≤120 days before study enrollment. 11. participation in other studies involving a study intervention within 28 days before randomization. anticipated participation in other studies within 28 days after receipt of study intervention in this study. 12. investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

1. a confirmed diagnosis of covid 19, rsv infection, or influenza ≤120 days before study intervention administration. 2. history of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 3. immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 4. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. 5. allergy to egg proteins (egg or egg products) or chicken proteins. 6. any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 7. receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study. 8. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study. 9. receipt of any rsv vaccine at any time prior to enrollment, or planned receipt throughout the study. 10. receipt of any influenza vaccine ≤120 days before study enrollment. 11. participation in other studies involving a study intervention within 28 days before randomization. anticipated participation in other studies within 28 days after receipt of study intervention in this study. 12. investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

a confirmed diagnosis of covid 19, rsv infection, or influenza ≤120 days before study intervention administration. history of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. allergy to egg proteins (egg or egg products) or chicken proteins. any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study. receipt of any rsv vaccine at any time prior to enrollment, or planned receipt throughout the study. receipt of any influenza vaccine ≤120 days before study enrollment. participation in other studies involving a study intervention within 28 days before randomization. anticipated participation in other studies within 28 days after receipt of study intervention in this study. investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

a confirmed diagnosis of covid 19, rsv infection, or influenza ≤120 days before study intervention administration. history of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. allergy to egg proteins (egg or egg products) or chicken proteins. any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study. receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study. receipt of any rsv vaccine at any time prior to enrollment, or planned receipt throughout the study. receipt of any influenza vaccine ≤120 days before study enrollment. participation in other studies involving a study intervention within 28 days before randomization. anticipated participation in other studies within 28 days after receipt of study intervention in this study. investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.